PL2331548T3 - Inhibitory proteazy - Google Patents
Inhibitory proteazyInfo
- Publication number
- PL2331548T3 PL2331548T3 PL09783391T PL09783391T PL2331548T3 PL 2331548 T3 PL2331548 T3 PL 2331548T3 PL 09783391 T PL09783391 T PL 09783391T PL 09783391 T PL09783391 T PL 09783391T PL 2331548 T3 PL2331548 T3 PL 2331548T3
- Authority
- PL
- Poland
- Prior art keywords
- protease inhibitors
- protease
- inhibitors
- Prior art date
Links
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0817424.5A GB0817424D0 (en) | 2008-09-24 | 2008-09-24 | Protease inhibitors |
| EP09783391.7A EP2331548B1 (en) | 2008-09-24 | 2009-09-24 | Protease inhibitors |
| PCT/EP2009/062406 WO2010034788A1 (en) | 2008-09-24 | 2009-09-24 | Protease inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2331548T3 true PL2331548T3 (pl) | 2014-03-31 |
Family
ID=39952074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09783391T PL2331548T3 (pl) | 2008-09-24 | 2009-09-24 | Inhibitory proteazy |
Country Status (22)
| Country | Link |
|---|---|
| US (11) | US8242119B2 (pl) |
| EP (1) | EP2331548B1 (pl) |
| JP (1) | JP5639592B2 (pl) |
| KR (1) | KR101671177B1 (pl) |
| CN (2) | CN103992329B (pl) |
| AU (1) | AU2009295898B2 (pl) |
| BR (1) | BRPI0918966B8 (pl) |
| CA (1) | CA2738023C (pl) |
| CY (1) | CY1114833T1 (pl) |
| DK (1) | DK2331548T3 (pl) |
| EA (1) | EA020122B1 (pl) |
| ES (1) | ES2438095T3 (pl) |
| GB (1) | GB0817424D0 (pl) |
| HR (1) | HRP20131131T1 (pl) |
| IL (1) | IL211811A (pl) |
| MY (1) | MY152969A (pl) |
| PL (1) | PL2331548T3 (pl) |
| PT (1) | PT2331548E (pl) |
| RS (1) | RS53054B (pl) |
| SI (1) | SI2331548T1 (pl) |
| WO (2) | WO2010034788A1 (pl) |
| ZA (1) | ZA201102179B (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
| GB201314503D0 (en) * | 2013-08-13 | 2013-09-25 | Medivir Ab | Cysteine protease inhibitor salt |
| CN107286150B (zh) * | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CN110563611B (zh) * | 2019-09-19 | 2021-02-02 | 中国医学科学院医药生物技术研究所 | 一种异羟肟酸类衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| JP3102101U (ja) | 2003-12-05 | 2004-07-02 | 株式会社ライトボーイ | 投光機 |
| JP2007513890A (ja) | 2003-12-12 | 2007-05-31 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害剤 |
| AU2005203972B2 (en) | 2004-01-08 | 2010-11-18 | Medivir Ab | Cysteine protease inhibitors |
| SE0400022D0 (sv) * | 2004-01-08 | 2004-01-08 | Medivir Ab | New compounds |
| FR2889701B1 (fr) | 2005-08-12 | 2007-10-05 | Sanofi Aventis Sa | Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique. |
| GB0614044D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| GB0614042D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| WO2008114054A1 (en) * | 2007-03-19 | 2008-09-25 | Medivir Ab | Protease inhibitors |
| US7893067B2 (en) * | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
| EP2240491B1 (en) | 2008-01-09 | 2015-07-15 | Amura Therapeutics Limited | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES |
| GB0817424D0 (en) | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
-
2008
- 2008-09-24 GB GBGB0817424.5A patent/GB0817424D0/en not_active Ceased
-
2009
- 2009-09-24 EA EA201170479A patent/EA020122B1/ru not_active IP Right Cessation
- 2009-09-24 DK DK09783391.7T patent/DK2331548T3/da active
- 2009-09-24 WO PCT/EP2009/062406 patent/WO2010034788A1/en not_active Ceased
- 2009-09-24 SI SI200930786T patent/SI2331548T1/sl unknown
- 2009-09-24 AU AU2009295898A patent/AU2009295898B2/en active Active
- 2009-09-24 HR HRP20131131AT patent/HRP20131131T1/hr unknown
- 2009-09-24 CN CN201410205405.9A patent/CN103992329B/zh active Active
- 2009-09-24 RS RS20130522A patent/RS53054B/sr unknown
- 2009-09-24 EP EP09783391.7A patent/EP2331548B1/en active Active
- 2009-09-24 US US12/739,489 patent/US8242119B2/en active Active
- 2009-09-24 KR KR1020117009274A patent/KR101671177B1/ko active Active
- 2009-09-24 CA CA2738023A patent/CA2738023C/en active Active
- 2009-09-24 PL PL09783391T patent/PL2331548T3/pl unknown
- 2009-09-24 CN CN200980148042.7A patent/CN102224156B/zh active Active
- 2009-09-24 BR BRPI0918966A patent/BRPI0918966B8/pt active IP Right Grant
- 2009-09-24 PT PT97833917T patent/PT2331548E/pt unknown
- 2009-09-24 MY MYPI20111288 patent/MY152969A/en unknown
- 2009-09-24 WO PCT/EP2009/062408 patent/WO2010034790A1/en not_active Ceased
- 2009-09-24 JP JP2011528326A patent/JP5639592B2/ja active Active
- 2009-09-24 ES ES09783391.7T patent/ES2438095T3/es active Active
-
2011
- 2011-03-17 IL IL211811A patent/IL211811A/en active IP Right Grant
- 2011-03-23 ZA ZA2011/02179A patent/ZA201102179B/en unknown
-
2012
- 2012-07-03 US US13/541,519 patent/US8426421B2/en active Active
-
2013
- 2013-03-14 US US13/831,267 patent/US8735395B2/en active Active
- 2013-11-18 CY CY20131101021T patent/CY1114833T1/el unknown
-
2014
- 2014-04-09 US US14/249,332 patent/US9200006B2/en active Active
-
2015
- 2015-11-13 US US14/940,817 patent/US9428517B2/en active Active
-
2016
- 2016-08-25 US US15/247,804 patent/US20170166538A1/en not_active Abandoned
-
2017
- 2017-08-02 US US15/667,292 patent/US20170334867A1/en not_active Abandoned
-
2018
- 2018-03-30 US US15/941,947 patent/US10329266B2/en not_active Expired - Fee Related
-
2019
- 2019-06-24 US US16/449,850 patent/US10723709B2/en not_active Expired - Fee Related
-
2020
- 2020-07-27 US US16/940,067 patent/US11312693B2/en active Active
-
2022
- 2022-04-25 US US17/728,943 patent/US12378209B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201008988B (en) | Hcv protease inhibitors | |
| ZA201100898B (en) | Novel inhibitors | |
| IL215506A0 (en) | Protease inhibitors | |
| EP2064177A4 (en) | PROTEASE INHIBITORS | |
| EP2313426A4 (en) | NEW PROTEASE INHIBITORS | |
| EP2509957A4 (en) | INHIBITORS OF CYSTEINE PROTEASES | |
| EP2358692A4 (en) | CYSTEINE PROTEASE INHIBITORS | |
| ZA201102179B (en) | Protease inhibitors | |
| ZA201102837B (en) | Phosphodiestarase inhibitors | |
| GB0817429D0 (en) | Enzyme inhibitors | |
| GB0817425D0 (en) | Protease inhibitors | |
| GB0714941D0 (en) | Inhibitors | |
| GB0712176D0 (en) | Protease inhibitors | |
| GB0705213D0 (en) | Protease inhibitors | |
| GB0700369D0 (en) | Protease inhibitors | |
| GB0712544D0 (en) | Protease inhibitors | |
| GB0712543D0 (en) | Protease inhibitors | |
| GB0700378D0 (en) | Protease inhibitors | |
| GB0705212D0 (en) | Protease inhibitors | |
| HK1154384A (en) | Protease inhibitors | |
| GB201019387D0 (en) | Inhibitors | |
| GB0816125D0 (en) | Novel inhibitors | |
| AU2008904159A0 (en) | Novel Protease Inhibitors | |
| GB0902661D0 (en) | Inhibitors | |
| GB0903650D0 (en) | Glyoalase inhibitors |